MoonLake Immunotherapeutics (MLTX) Depreciation & Amortization (CF) (2021 - 2026)

MoonLake Immunotherapeutics' Depreciation & Amortization (CF) history runs 6 years deep, the most recent figure standing at $800000.0 for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 111.64% year-over-year to $800000.0 in Q1 2026; TTM through Mar 2026 was $3.0 million, a 109.52% increase from a year earlier, with the FY2025 full-year figure at $2.6 million, up 86.86% from the prior year.
• Depreciation & Amortization (CF) grew to $800000.0 in Q1 2026 per MLTX's latest filing, from $716000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $800000.0 in Q3 2025 and bottomed at $2488.0 in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $321000.0 (2024), against an average of $284795.1.
• Across the five-year window, Depreciation & Amortization (CF) sank 33.84% in 2022 and soared 11423.26% in 2024, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $3289.0 in 2022, then changed by 0.0% to $3289.0 in 2023, then surged by 11423.26% to $379000.0 in 2024, then surged by 88.92% to $716000.0 in 2025, then gained by 11.73% to $800000.0 in 2026.
• Per Business Quant, the three latest MLTX Depreciation & Amortization (CF) figures stand at $800000.0 (Q1 2026), $716000.0 (Q4 2025), and $800000.0 (Q3 2025).